Clinical Research on the Use of Immune Checkpoint Inhibitors Combined With Chidamide for the Functional Cure of AIDS

NCT ID: NCT06902038

Last Updated: 2025-03-30

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 33 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-03-22
• Study Completion Date: 2027-12-31

Brief Summary

Evaluate the efficacy and safety of immune checkpoint inhibitors combined with chidamide as an "activate and kill" strategy to extend viral rebound time, reduce the HIV reservoir, and achieve functional cure.

Detailed Description

This project plans to conduct a prospective randomized controlled study, using immune checkpoint inhibitors combined with chidamide, while applying antiretroviral therapy interruption(ATI) to further enhance the immune killing effect of this strategy, with the aim of accelerating the clearance of the HIV reservoir and delaying the time of viral rebound, thereby achieving a functional cure for AIDS.

Conditions

HIV-1 Infection

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Control group

Saline 50ml q3w ×2

Group Type: PLACEBO_COMPARATOR

Saline (NaCl 0,9 %) (placebo)

Intervention Type: DRUG

Saline 50ml Q3W ×2

Experimental sindilizumab

100mg of sindilizumab, was dissolved in 50ml normal saline, q3w was administered ×2

Group Type: EXPERIMENTAL

PD-1 inhibitor

Intervention Type: DRUG

100mg of sindilizumab, was dissolved into 50ml of normal saline q3w ×2

Experimental sindilizumab and sidarbenamide

100mg of sindilizumab, was dissolved into 50ml of normal saline q3w ×2+ sidarbenamide 10mg biw orally for 2 weeks

Group Type: EXPERIMENTAL

PD-1 inhibitor

Intervention Type: DRUG

100mg of sindilizumab, was dissolved into 50ml of normal saline q3w ×2

Sidarbenamide

Intervention Type: DRUG

Sidarbenamide 10mg biw orally for 2 weeks

Interventions

PD-1 inhibitor

100mg of sindilizumab, was dissolved into 50ml of normal saline q3w ×2

Intervention Type: DRUG

Sidarbenamide

Sidarbenamide 10mg biw orally for 2 weeks

Intervention Type: DRUG

Saline (NaCl 0,9 %) (placebo)

Saline 50ml Q3W ×2

Intervention Type: DRUG

Other Intervention Names

Placebo Comparator

Eligibility Criteria

Inclusion Criteria

• People diagnosed with HIV infection;
• Age ≥18 years old;
• General good health, body mass index ≥18.0 to <35.0 kg/m2;
• Able and willing to comply with the time requirements for research visits and evaluations;
• have received ART therapy for at least 24 months, and plasma HIV-1 RNA < 50 copies /ml for two consecutive times with a time interval of at least 12 months;
• During the screening period, the number of CD4+ T cells was ≥350 cells /μl(including boundary values);
• Agree to adhere to contraception during the course of participating in the project and within 6 months after the end of the trial;
• Willing to sign informed consent

Exclusion Criteria

• Have suffered from any serious acute disease within 8 weeks;
• Subjects with a history of active autoimmune disease or autoimmune disease requiring systemic treatment;
• Pre-treatment/exposure to any other immune checkpoint inhibitor [e.g., anti-programmed cell death protein 1(PD-1), anti-PD-L1, anti-PD-L2, anti-CTLA4, etc.].
• The patient has received the following treatment:

1. Received other anti-latency drugs within 30 days prior to enrollment;

2. Radiotherapy or chemotherapy 30 days before screening;

3. Immunosuppressive therapy 60 days before screening;

4. Treatment with immunomodulators (e.g., interleukin, interferon), hydroxyurea, or phosphonic acid 60 days prior to screening

5. Receiving HIV vaccine or systemic cytotoxic chemotherapy 60 days before screening;

6. Previous immunoglobulin (IgG) therapy

7. Received blood transfusion or cell growth factor therapy in the 90 days prior to screening

8. Drugs such as rifampicin and rifambutin were being used at the time of screening or at the planned treatment stage;

• Laboratory tests meet the following standards:

1. Absolute neutrophil count (ANC) < 1.50×109/L; Hemoglobin (Hb) < 105g/L(male) or < 95g/L(female); Platelet < 75×109/μL; International Normalized Ratio (INR) > 1× Upper Limit of Normal (ULN)

2. Serum alanine aminotransferase (ALT) > 1.5× upper limit of normal (ULN), serum aspartate aminotransferase (SGOT/AST) > 1.5× upper limit of normal (ULN), total bilirubin, direct bilirubin > 1.5× upper limit of normal (ULN), serum creatinine > 1.5× upper limit of normal (ULN), And the abnormality has clinical significance;

3. Five abnormalities of thyroid function with clinical significance: test items include triiodothyronine (T3), tetraiodothyronine (T4), free triiodothyronine (FT3), free tetraiodothyronine (FT4), and thyroid stimulating hormone (TSH).

4. The epinephrine test was abnormal and clinically significant;

5. Blood glucose and glycated hemoglobin were abnormal and clinically significant

• Twelve-lead electrocardiogram was abnormal and clinically significant at the time of enrollment;
• Interstitial changes were detected by chest CT at the time of enrollment;
• Subjects with severe heart disease, symptomatic or asymptomatic arrhythmia;
• Patients with co-infection such as HBV, HCV, syphilis, diabetes, and other liver diseases;
• Subjects with a history of active or suspected malignancy or malignancy (other than basal cell skin cancer or cervical cancer in situ) within five years.
• Subjects with a history of tuberculosis or active tuberculosis.
• Subjects with psychiatric or substance abuse disorders known to interfere with the requirements of the experiment.
• Subjects who received immunomodulatory or immunosuppressive therapy in the 24 weeks prior to first taking the study drug.
• Pregnant and lactating women;
• Mental illness or drug abuse interferes with the conduct of the test.
• Histone deacetylase inhibitors, such as valproic acid, butyrate, phenyl butyrate, etc., but can be included after a 28-day washout period;
• Patients with severe cardiac insufficiency [New York College of Cardiology (NYHA) Grade IV for cardiac insufficiency];
• any arterial thromboembolism event, including myocardial infarction, unstable angina pectoris, cerebrovascular accident, or transient ischemic attack, occurred within 6 months prior to treatment induction; Standardized treatment of uncontrolled hypertension (systolic blood pressure ≥150mmHg or diastolic blood pressure ≥100mmHg); Cardiomyopathy;
• Patients had significant QT/QTC intervals during the screening period (Fridericia formula: QTcF=QT/RR0.33) prolonged (e.g., repeated measurements show a QTc interval >450 ms, or there is another risk of torsive ventricular TdP [e.g., heart failure, hypokalemia, familial long QT syndrome]) or combined use of drugs that may cause a prolonged QT/QTc interval;
• Allergic or anti-drug antibodies to the drug or excipient used in this test are known.

The researchers judged that they were not suitable to participate in this experiment.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Jun Chen, MD

OTHER_GOV

Sponsor Role: lead

Responsible Party

Jun Chen, MD

Deputy Director of Infection and Immunization

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Jun Chen, MD

Role: PRINCIPAL_INVESTIGATOR

Shanghai Public Health Clinical Center

Central Contacts

Jun Chen, MD

Role: CONTACT

qtchenjun@163.com

021-37990333

Other Identifiers

PD-1 inhibitor

Identifier Type: -

Identifier Source: org_study_id